Henan Medinno Pharmaceutical Technology Co. Ltd. has identified deuterated non-receptor tyrosine-protein kinase TYK2 and tyrosine-protein kinase JAK1, JAK2 and JAK3 inhibitors reported to be useful for the treatment of allergy, asthma, cancer, dermatological disorders, diabetes, eye disorders, neurodegeneration and transplant rejection, among others.

Pharmaengine Inc. has synthesized protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.

Cancer Targeted Technology LLC has disclosed conjugates comprising a glutamate carboxypeptidase 2 (FOLH1; NAALAD1; PSMA) targeting ligand covalently linked to a therapeutic or diagnostic agent through a linker reported to be useful for the treatment of prostate cancer.

Accent Therapeutics Inc. has described ATP-dependent RNA helicase A (DHX9) inhibitors reported to be useful for the treatment of cancer.

Transthera Biosciences Co. Ltd. has divulged NLRP3 inflammasome inhibitors reported to be useful for the treatment of autoimmune diseases and inflammatory disorders.

Abbisko Therapeutics Co. Ltd. has identified EGFR mutant inhibitors reported to be useful for the treatment of cancer.

Merck Sharp & Dohme LLC has synthesized viral replication inhibitors reported to be useful for the treatment of respiratory syncytial virus and metapneumovirus infections.

Sanofi SA has described Mas-related G-protein coupled receptor member X2 (MRGPRX2) antagonists reported to be useful for the treatment of allergy, pain, dermatological and inflammatory disorders.

Novartis AG has divulged mitogen-activated protein kinase 1 (MAPK1; ERK2) inhibitors reported to be useful for the treatment of cancer.